Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
Mini Rev Med Chem
; 21(12): 1431-1456, 2021.
Artículo
en Inglés
| MEDLINE | ID: covidwho-999944
ABSTRACT
Recently, a sudden outbreak of novel coronavirus disease (COVID-19) was caused by a zoonotic virus known as severe acute respiratory syndrome coronavirus (SARS-CoV-2). It has caused pandemic situations around the globe affecting the lives of millions of people. So far, no drug has been approved for the treatment of SARS-CoV-2 infected patients. As of now, more than 1000 clinical trials are going on for repurposing of FDA-approved drugs and for evaluating the safety and efficiency of experimental antiviral molecules to combat COVID-19. Since the development of new drugs may require months to years to reach the market, this review focusses on the potential of existing small molecule FDA approved drugs and the molecules already in the clinical pipeline against viral infections like HIV, hepatitis B, Ebola virus, and other viruses of coronavirus family (SARS-CoV and MERS-CoV). The review also discusses the natural products and traditional medicines in clinical studies against COVID-19. Currently, 1978 studies are active, 143 completed and 4 posted results (as of June 13, 2020) on clinicaltrials.gov.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Ensayos Clínicos como Asunto
/
Descubrimiento de Drogas
/
Reposicionamiento de Medicamentos
/
SARS-CoV-2
/
Tratamiento Farmacológico de COVID-19
Tipo de estudio:
Estudio experimental
/
Estudio observacional
/
Estudio pronóstico
/
Ensayo controlado aleatorizado
Límite:
Humanos
Idioma:
Inglés
Revista:
Mini Rev Med Chem
Asunto de la revista:
Química
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
1389557521666201228145755
Similares
MEDLINE
...
LILACS
LIS